DABIPLA 110MG CAPSULE 10'S

DABIPLA 110MG CAPSULE 10'S offers a more convenient dosing regimen, does not require routine monitoring, and has a reduced risk of bleeding complications compared to WARFARIN.

No, it is important to follow your doctor's instructions and not discontinue DABIPLA 110MG CAPSULE 10'S without medical guidance, as it may increase the risk of blood clots.

If you miss a dose, take it as soon as you remember. If it is close to the time of your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

DABIPLA 110MG CAPSULE 10'S may interact with certain medications, including antiplatelet drugs, other anticoagulants, and certain antibiotics. Inform your healthcare provider about all the medications you are taking to avoid potential drug interactions.

Unlike WARFARIN, routine monitoring of blood parameters (such as INR) is not necessary with DABIPLA 110MG CAPSULE 10'S. However, your doctor may perform occasional blood tests to assess your kidney function.

Seek immediate medical attention if you experience uncontrolled bleeding, excessive bruising, or any signs of bleeding complications while taking DABIPLA 110MG CAPSULE 10'S.

DABIPLA 110MG CAPSULE 10'S is generally not recommended during pregnancy unless the potential benefits outweigh the risks. Consult your doctor for personalized advice.

DABIPLA 110MG CAPSULE 10'S may not be suitable for individuals with certain medical conditions, such as severe liver disease, active bleeding, or hypersensitivity to the medication. It is important to discuss your medical history with your healthcare provider before starting treatment.